Shares of Crispr Theraptc (NASDAQ:CRSP) have received a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $21.25.
A number of research firms recently commented on CRSP. SunTrust Banks, Inc. reaffirmed a “hold” rating and issued a $16.00 price target on shares of Crispr Theraptc in a report on Friday, November 10th. Cann reaffirmed a “hold” rating on shares of Crispr Theraptc in a report on Thursday, November 9th. Barclays PLC reaffirmed a “buy” rating and issued a $29.00 price target on shares of Crispr Theraptc in a report on Friday, September 8th. Chardan Capital reaffirmed a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th.
Crispr Theraptc (CRSP) opened at $17.46 on Wednesday. Crispr Theraptc has a 1 year low of $11.63 and a 1 year high of $25.00.
Crispr Theraptc (NASDAQ:CRSP) last posted its earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Theraptc had a negative return on equity of 38.42% and a negative net margin of 466.58%. The firm had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. During the same period in the prior year, the business earned ($2.77) EPS. Crispr Theraptc’s quarterly revenue was up 54.2% compared to the same quarter last year. sell-side analysts anticipate that Crispr Theraptc will post -2.49 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://weekherald.com/2017/11/15/crispr-theraptc-crsp-receives-consensus-recommendation-of-hold-from-analysts.html.
In related news, insider Samarth Kulkarni sold 27,154 shares of Crispr Theraptc stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $20.08, for a total value of $545,252.32. Following the completion of the transaction, the insider now directly owns 110,893 shares in the company, valued at approximately $2,226,731.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Rodger Novak sold 18,470 shares of Crispr Theraptc stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $20.76, for a total transaction of $383,437.20. Following the completion of the transaction, the chief executive officer now owns 1,148,007 shares of the company’s stock, valued at $23,832,625.32. The disclosure for this sale can be found here. Insiders sold a total of 287,491 shares of company stock worth $5,690,085 in the last ninety days. 39.98% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in CRSP. Allianz Asset Management GmbH purchased a new position in Crispr Theraptc in the 3rd quarter valued at approximately $2,384,000. Granahan Investment Management Inc. MA grew its stake in Crispr Theraptc by 51.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after buying an additional 89,839 shares in the last quarter. Credit Suisse AG purchased a new position in Crispr Theraptc in the 1st quarter valued at approximately $1,742,000. Adams Street Partners LLC purchased a new position in Crispr Theraptc in the 3rd quarter valued at approximately $1,019,000. Finally, Hershey Trust Co. purchased a new position in Crispr Theraptc in the 3rd quarter valued at approximately $768,000. Institutional investors and hedge funds own 25.61% of the company’s stock.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.